Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 266765


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Delivery
  • Disease
  • Radiation
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 266765

License Grant
For the License to the Kaminski Patent Family and Wahl Patent Family, the Licensors each each grant to the Licensor a worldwide, irrevocable, non-exclusive license to for any and all purposes.
License Property
The Kaminski Patent Family shall mean U.S. Patents No. 6,015,542, 6,090,365, 5,595,721, 5,843,398, 6,287,537, and 6,565,827, including associated derivatives.  this includes the ZevalinTM Therapeutic Regimen.  ZevalinTM Kits refer to any kit containing Ibritumomab Tiuxetan for the preparation of Indium-111 Ibritumomab Tiuxetan and Yttrium-90 Ibritumomab Tiuxetan as currently formulated and approved by the FDA.

The Wahl Patent Family shall mean U.S. Patents No. 6,251,362, and 6,022,521, including associated derivatives.

Field of Use
The field of use is all uses.  ZevalinTM Kits relate to the treatment of any B-cells malignancies.

The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are 'blood cancers' in the lymph nodes. They develop more frequently in older adults and in immunocompromised individuals. B-cell lymphomas include both Hodgkin's lymphomas and most non-Hodgkin lymphomas.

IPSCIO Record ID: 46309

License Grant
The Company entered into an Exclusive License Agreement with Licensee for U.S. and Canadian rights to the Company's bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. This license agreement is for BENDEKAâ„¢.
License Property
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL for treatment of patients with chronic lymphocytic leukemia, ('CLL') and patients with non-Hodgkin's lymphoma ('NHL').
Field of Use
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

IPSCIO Record ID: 26654

License Grant
We entered into an agreement giving us worldwide rights to use two proprietary hybridoma cell lines that are used in the production of BiovaxID with the University. These are the same cell lines that have been used by researchers at Stanford and the National Cancer Institute to perform their studies of the hybridoma idiotype vaccine in non-Hodgkins lymphoma. This agreement gives us exclusive rights to these cell lines through 2019 in the fields of B-cell and T-cell cancers, and it gives us non-exclusive rights in such fields of use at all times after 2019. The agreement also gives us the right to sublicense or transfer the licensed biological materials to collaborators in the licensed fields.
License Property
Biovaxid is a randomized phase III vaccine clinical research study being conducted at several cancer centers and clinics in the United States to compare two types of vaccine treatments for people with Stage III or IV follicular lymphoma — a type of cancer in the lymph nodes.
Field of Use
The rights granted apply to the medical field, primarily to cancer.

IPSCIO Record ID: 328141

License Grant
The Swiss University hereby grants to Licensee, and Licensee hereby accepts, a license under Patent Rights to make and have made, use, sell, offer for sale, and import Licensed Products in the Field within the Territory and during the Term.
License Property
Patent Rights means any of the following  the PCT patent application entitled 'Treatment of B-cell lymphoma with microRNA', publication number WO 2012/041959.

MicroRNAs are naturally occurring, short ribonucleic acid, or RNA, molecules, or oligonucleotides, that play a critical role in regulating key biological pathways.

Field of Use
Field of use is for treatment of certain types of B-cell lymphoma with microRNA.
B-cell lymphoma is a type of cancer present in the lymph system.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.